Acurx Pharmaceuticals Set to Present at A.G.P. Healthcare Showcase on New Antibiotics

Acurx Pharmaceuticals to Showcase at A.G.P. Healthcare Event

Acurx Pharmaceuticals, a promising biopharmaceutical company, is preparing to present at the upcoming Alliance Global Partners (A.G.P.) Healthcare Company Showcase. This event is scheduled for May 21, 2025, and will feature a virtual fireside chat with David P. Luci, the company’s President and CEO, at 9:00 AM ET. The presentation will provide insights into their lead antibiotic candidate, ibezapolstat, which is moving towards international Phase 3 clinical trials for the treatment of C. difficile infections, a challenging type of bacterial infection.

Acurx Pharmaceuticals specializes in developing a new class of small molecule antibiotics aimed at effectively combating difficult bacterial infections, particularly those that are resistant to conventional treatments. The company's innovative approach focuses on creating antibiotics that selectively target Gram-positive bacteria, a group that includes several notorious pathogens responsible for severe infections.

The lead candidate, ibezapolstat (IBZ), is designed to inhibit the bacterial enzyme DNA polymerase IIIC, which is essential for DNA replication in specific bacteria. By blocking this enzyme, ibezapolstat aims to cause the death of Gram-positive bacteria, including those responsible for C. difficile infection (CDI). This makes Acurx's work particularly relevant in today's medical landscape, where antibiotic resistance is a growing concern.

The upcoming presentation by Acurx will not only highlight ibezapolstat's potential but also provide updates on the company's broader research and development pipeline. This includes other antibiotic candidates targeting Gram-positive bacteria like Methicillin-resistant Staphylococcus aureus (MRSA) and Vancomycin-resistant Enterococcus (VRE), as well as weaponizing against emerging threats such as drug-resistant Streptococcus pneumoniae and B. anthracis, which is associated with anthrax.

Acurx’s commitment to addressing these pressing healthcare needs is evident through its advanced drug development efforts. The company has made significant progress and is now on the brink of commencing international clinical trials for ibezapolstat, further underscoring its potential to be a game-changer in the fight against serious bacterial infections.

Following the event, a live webcast will be available on Acurx's website, providing an opportunity for those unable to attend to catch up on the crucial information presented. A replay of the discussion can be accessed in the News/Events section of their site, ensuring that stakeholders and interested parties can remain informed about the company's developments.

For those who wish to delve deeper into Acurx Pharmaceuticals' initiatives and its promising drug pipeline, additional details can be found at www.acurxpharma.com.

This participation at A.G.P. not only reflects Acurx's active engagement with the healthcare investment community but also highlights the urgent need for new and effective therapies in the realm of antibiotic-resistant infections. The company’s pioneering work holds hope for better management of these challenging conditions, aligning with the ongoing efforts in the pharmaceutical industry to innovate against a backdrop of rising resistance.

As the healthcare landscape continues to evolve, Acurx Pharmaceuticals stands at the forefront, poised to make a significant impact in the treatment of difficult-to-treat bacterial infections. Investors and healthcare professionals alike will surely be watching closely as the findings from the A.G.P. Healthcare Company Showcase unfold.

With its progressive approach, Acurx is not only preparing to introduce critical solutions to the market but is also advocating for a new era in antibiotic development amidst increasing global health challenges.